Cargando…
HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom's Macroglobulinemia
Ibrutinib is a major new addition to the therapeutic armamentarium for chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, and chronic graft versus host disease. Though ibrutinib has proven to be a revolutionary new small molecule agent, and has relatively minim...
Autor principal: | Wallace, Mark R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125491/ https://www.ncbi.nlm.nih.gov/pubmed/32274227 http://dx.doi.org/10.1155/2020/6516037 |
Ejemplares similares
-
Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia
por: Poza, María, et al.
Publicado: (2021) -
Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
por: Papanota, Aristea-Maria, et al.
Publicado: (2019) -
Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
por: Büyükkurt, Nurhilal, et al.
Publicado: (2023) -
A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
por: Castillo, Jorge J., et al.
Publicado: (2022) -
Ventricular Tachycardia Storm in a Patient Treated With Ibrutinib for Waldenstrom Macroglobulinemia
por: Madgula, Anantha Sriharsha, et al.
Publicado: (2020)